7KDD image
Deposition Date 2020-10-08
Release Date 2021-03-17
Last Version Date 2024-11-20
Entry Detail
PDB ID:
7KDD
Title:
HCMV postfusion gB in complex with SM5-1 Fab
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.50 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Envelope glycoprotein B
Gene (Uniprot):gB
Chain IDs:A, D (auth: B), G (auth: C)
Chain Length:907
Number of Molecules:3
Biological Source:Human cytomegalovirus (strain Towne)
Polymer Type:polypeptide(L)
Molecule:SM5-1 Fab antibody heavy chain
Chain IDs:B (auth: D), E (auth: F), H
Chain Length:261
Number of Molecules:3
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:SM5-1 Fab antibody light chain
Chain IDs:C (auth: E), F (auth: G), I
Chain Length:215
Number of Molecules:3
Biological Source:Homo sapiens
Primary Citation
Prefusion structure of human cytomegalovirus glycoprotein B and structural basis for membrane fusion.
Sci Adv 7 ? ? (2021)
PMID: 33674318 DOI: 10.1126/sciadv.abf3178

Abstact

Human cytomegalovirus (HCMV) causes congenital disease with long-term morbidity. HCMV glycoprotein B (gB) transitions irreversibly from a metastable prefusion to a stable postfusion conformation to fuse the viral envelope with a host cell membrane during entry. We stabilized prefusion gB on the virion with a fusion inhibitor and a chemical cross-linker, extracted and purified it, and then determined its structure to 3.6-Å resolution by electron cryomicroscopy. Our results revealed the structural rearrangements that mediate membrane fusion and details of the interactions among the fusion loops, the membrane-proximal region, transmembrane domain, and bound fusion inhibitor that stabilized gB in the prefusion state. The structure rationalizes known gB antigenic sites. By analogy to successful vaccine antigen engineering approaches for other viral pathogens, the high-resolution prefusion gB structure provides a basis to develop stabilized prefusion gB HCMV vaccine antigens.

Legend

Protein

Chemical

Disease

Primary Citation of related structures